Keyphrases
Follow-on Products
100%
Non-biological Complex Drugs
100%
United States
100%
European Union
100%
Marketing Approval
100%
Regulatory Decision Making
100%
Cell-based
100%
Japan
100%
Gene Therapy
100%
Marketing Risk
50%
Postmarketing
50%
Confirmatory Data
33%
Safety Risk
33%
Uncertain Risk
33%
Assessment Procedures
33%
Product Characteristics
33%
Scientific Uncertainty
33%
Risk Management
33%
Binary Decision-making
16%
Multiple Jurisdictions
16%
Orphan Designation
16%
Risk Management Activities
16%
Regulatory Assessment
16%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Unmet Medical Need
16%
Decision-making Approach
16%
Adaptive Approach
16%
Cellular Products
16%
Regulatory Agencies
16%
Clinical Progress
16%
Clinical Benefit
16%
Complex Drug Product
15%
Pharmacology, Toxicology and Pharmaceutical Science
Chimeric Antigen Receptor
100%
Biological Product
100%
Generic Drug
50%
Biosimilar Agent
50%
Iron
50%
